QUIXIDAR 5mg / 0.4ml injectable solution pre-filled syringe medication leaflet

B01AX05 fondaparinux sodium • Blood and blood forming organs | Antithrombotic agents | Other antithrombotic agents

Fondaparinux sodium is an anticoagulant medication used to prevent and treat blood clots, such as deep vein thrombosis or pulmonary embolism. It works by inhibiting a key factor involved in blood coagulation, thereby reducing the risk of dangerous clot formation.

It is administered by subcutaneous injection, usually once daily, as directed by the doctor. The dose is determined based on body weight and the patient's individual risk. It is important to follow the treatment regularly and not to stop it without medical advice.

Side effects may include bleeding, bruising at the injection site, anemia, or, more rarely, allergic reactions. In very rare cases, serious complications such as a decrease in platelet count or severe hypersensitivity reactions may occur.

Fondaparinux sodium is an effective and safe option for preventing thrombotic complications, but it requires careful monitoring and strict adherence to medical recommendations to minimize the risks associated with treatment.

General data about QUIXIDAR 5mg / 0.4ml

Substance: fondaparinux sodium

Date of last drug list: 01-07-2013

Commercial code: W51702003

Concentration: 5mg / 0.4ml

Pharmaceutical form: injectable solution pre-filled syringe

Quantity: 10

Product type: original

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Pharmaceutical forms available for fondaparinux sodium

Concentrations available for fondaparinux sodium

1.5mg/0.3ml, 10mg/0.8ml, 2.5mg/0.5ml, 5mg/0.4ml, 7.5mg/0.6ml

Other substances similar to fondaparinux sodium